Liver/Biliary
  • Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag, an oral small molecule agonist of the thrombopoietin receptor, achieves and maintains target platelet count in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures, researchers report in a phase 3, placebo-controlled trial published in the May issue of Clinical Gastroenterology and Hepatology. The drug caused no significant

Read more
  • How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

The G-protein–coupled estrogen receptor (GPER1) is a hepatic sensor of estrogen that regulates liver growth during development, regeneration, and tumorigenesis, researchers show in a study of zebrafish and human liver published in the May issue of Gastroenterology. Inhibitors of GPER1 might be developed for liver cancer prevention or treatment. Liver cancer

Read more
  • Is Bariatric Surgery the Best Treatment for NAFLD?

Is Bariatric Surgery the Best Treatment for NAFLD?

Bariatric surgery completely resolves non-alcoholic fatty liver disease (NAFLD) in obese patients, researchers report in the May issue of Clinical Gastroenterology and Hepatology. However, The meta-analysis also found that some patients develop new or worsened features of NAFLD after these surgical weight-loss procedures. NAFLD is characterized by hepatic steatosis that

Read more

Is an Endoscopic Transluminal Approach Better Than Surgery for Patients With Necrotizing Pancreatitis?

An endoscopic transluminal approach for treatment of infected necrotizing pancreatitis, compared with minimally invasive surgery, significantly reduced major complications, lowered costs, and increased quality of life, according to a randomized trial published in the March issue of Gastroenterology. Acute pancreatitis is the third most common gastrointestinal disorder in the United

Read more
  • Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

A Markov-based mathematical model estimates that transplanting hepatitis C virus (HCV)-positive livers into HCV-negative patients who have received direct-acting antiviral (DAA) agents would be cost effective and improve outcomes, researchers report in the March issue of Clinical Gastroenterology and Hepatology. There has been a steady increase in the number of

Read more
  • REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

CRISPR-Cas9 technology can be used to engineer organoids for studies of gastrointestinal development and disease pathogenesis. In the February issue of Gastroenterology, Masayuki Fujii et al review derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 has advanced studies of the digestive system. CRISPR-Cas9 genome editing technology allows researchers to

Read more
  • What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

Maintained virologic response to entecavir or lamivudine associates with short- and long-term transplant-free survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis, researchers report in the December issue of Clinical Gastroenterology and Hepatology. The benefits are maintained for up to 10 years, but patients are still at risk for

Read more
  • Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Liver allocation based on model for end-stage liver disease-sodium (MELD-Na) score improved waitlist outcomes and provided significant benefit to patients with hyponatremia, researchers report in the November issue of Gastroenterology. However, there are discrepancies in transplantation survival benefit, so current rules for liver allocation might require revision, the authors state. The

Read more
  • Should We Screen for HCC?

Should We Screen for HCC?

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) by abdominal ultrasonography (USS) and/or measurement of serum level of alpha-fetoprotein (AFP) is not associated with reduced mortality from this cancer, reseachers report from a matched case–control study in the October issue of Gastroenterology. Patients with cirrhosis have a high risk (1%–8%

Read more